Gilead Sciences, Inc.

Odyssey Thera Inc.

Helen Yu

William John Watkins

Chandrasekar Venkataramani

Peter A Blomgren

Musong Kim

Zhimin Du

Suet Chung Yeung

Julian Andrew Codelli

Stephen William Watson Michnick

Gayatri Balan

Rhiannon Thomas-Tran

Gregg M Schwarzwalder

Brian A Carr

Ingrid Remy

Nathan D Thomsen

Heather Stephenson

Craig S Pace

Xue Zhang

Matthew Robert Schenauer

Mini Balakrishnan

Marnie L MacDonald

Doug Rehder

Jane Lamerdin

John K Westwick

Michael T Tudesco

Chen Chen

Loredana Serafini

Dorothée Saddier Axe

Brian M Weist

Michael Graupe

Yunfeng Eric Hu

Tomas Cihlar

Magdeleine S Hung

Manu Kanwar

Derek Dean Sloan

George Stepan

Jeffrey Patrick Murry

Marnie Macdonald

The present disclosure relates generally to compounds that bind to and act as degraders of an IKAROS Family Zinc Finger (IKZF) protein, such as IKZF2 (Helios) and/or IKZF4 (Eos). The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding and degradation of an IKZF protein, such as IKZF2 and/or IKZF4, including cancer.

IKAROS Zinc Finger Family degraders and uses thereof

Antibodies that bind to HIV gp120 and neutralize HIV are disclosed. Also disclosed are methods of using such antibodies alone or in combination with other therapeutic agents to treat or prevent HIV infection.

Antibodies that target HIV gp120 and methods of use

IKAROS zinc finger family degraders and uses thereof

Antibodies that target HIV GP120 and methods of use

Provided are compounds, compositions, combinations, kits, uses, and methods for treating HIV in a human being using such compounds or combinations with proteasome inhibitors.

Compounds and combinations for the treatment of HIV

The present invention provides protein fragment complementation assays for drug discovery, in particular to identify compounds that activate or inhibit cellular pathways. Based on the selection of an interacting protein pair combined with an appropriate PCA reporter, the assays may be run in high-throughput or high-content mode and may be used in automated screening of libraries of compounds. The interacting pair may be selected by cDNA library screening; by gene-by-gene interaction mapping; or by prior knowledge of a pathway. Fluorescent and luminescent assays can be constructed using the methods provided herein. The selection of suitable PCA reporters for high-throughput or high-content (high-context) assay formats is described for a diversity of reporters, with particular detail provided for examples of monomeric enzymes and fluorescent proteins. Methods are described for constructing such assays for one or more steps in a biochemical pathway; testing the effects of compounds from combinatorial, natural product, peptide, antibody, nucleic acid or other diverse libraries on the protein or pathway(s) of interest; and using the results of the screening to identify specific compounds that activate or inhibit the protein or pathway(s) of interest. Single-color and multi-color assays are disclosed. Further disclosed are universal expression vectors with cassettes that allow the rapid construction of assays for a large and diverse number of gene/reporter combinations. The development of such assays is shown to be straightforward, providing for a broad, flexible and biologically relevant platform for drug discovery.

Protein fragment complementation assays for high-throughput and high-content screening

The present invention provides protein single-color and multi-color protein fragment complementation assays for drug discovery, in particular to identify compounds that activate or inhibit cellular pathways. Based on the selection of an interacting protein pair combined with an appropriate PCA reporter such as monomeric enzymes and fluorescent proteins, the assays may be run in high-throughput or high-content mode and may be used in automated screening of libraries of compounds. Methods are described for constructing such assays for one or more steps in a biochemical pathway; testing the effects of compounds from combinatorial, natural product, peptide, antibody, nucleic acid or other diverse libraries on the protein or pathway(s) of interest; and using the results of the screening to identify specific compounds that activate or inhibit the protein or pathway(s) of interest. The development of such assays provides for a broad, flexible and biologically relevant platform for drug discovery.

Growing community of inventors

Mountain View, CA, United States of America

Helen Yu